An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-jRCT2080224848
- Lead Sponsor
- Taisho Pharmaceutical Co.Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 505
Inclusion Criteria
(1)At visit1(-4 weeks), Subject must be fully informed about the study and must obtain written informed consent from the subject himself.
(2)At Visit2(0 week), Subjects must have completed the previous study (TS152-3000-JA or TS152-3001-JA) ,and must have completed all evaluations required at the follow-up visit.
etc.
Exclusion Criteria
Subjects who had serious adverse drug reactions in the previous study.
At Visit1(-4 weeks) or Visit2 (0 week), Subjects who have not recovered from clinically important adverse events.
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method